gen received an option to obtain an exclusive license to Cytokinetics' cardiac contractility program, (including the lead drug candidate, CK-1827452). Under the terms of the agreement, Cytokinetics is eligible to receive pre-commercialization and commercialization milestone payments of up to $600 million on CK-1827452 and other products arising from the collaboration, and royalties that escalate based on increasing levels of annual net sales of products commercialized under the agreement. Cytokinetics also has the opportunity to earn increased royalties by sharing certain Phase 3 development costs. In that case, Cytokinetics could co-promote products in North America and would have an agreed role in commercialization activities in North America. The collaboration is worldwide, excluding Japan.
Development Status of CK-1827452
CK-1827452, a novel cardiac myosin activator, has been the subject of a clinical trials program comprised of multiple Phase 1 and Phase 2a trials. This program was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of both intravenous and oral formulations of CK-1827452 for the potential treatment of heart failure across the continuum of care, in both hospital and outpatient settings. Two Phase 2a clinical trials of CK-1827452 from this program have been completed, and two Phase 2a clinical trials of CK-1827452 are ongoing.
The first Phase 2a clinical trial evaluated CK-1827452 in patients with stable heart failure. Data from that trial were recently presented at the American College of Cardiology Meeting in March 2009. Cytokinetics plans to present additional analyses from this trial at a Late Breaking Trial session at the 2009 Heart Failure Congress of the European Society of Cardiology, to be held from May 30 - June 2 in Nice, France. The second Phase 2a clinical trial was designed to evaluate an intravenous formulation together with an oral foPage: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
. Amgen Announces Voting Results Of Annual Meeting Of Stockholders2
. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign3
. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR4
. Amgen to Present at the Cowen and Company Annual Healthcare Conference5
. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab6
. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.557
. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services8
. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results9
. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference10
. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe11
. Amgen Positioned to Deliver Attractive Growth Over Next Five Years